REGN:Regeneron Pharmaceuticals Inc Snapshot | Charting | News | Options
$567.12 NASDAQ 2:31p ET
October 8 '25 		Libtayo(R) (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment o... GlobeNewswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story Top Stories on REGN
    No News Available
    Regeneron to Report Third Quarter 2025 Financial and Operating Result...
    4:05p ET September 30 '25 GlobeNewswire
    Evkeeza(R) (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. fo...
    7:00a ET September 26 '25 GlobeNewswire
    Press Release: Sanofi and Regeneron's Dupixent to treat chronic spont...
    12:30a ET September 22 '25 GlobeNewswire
    Dupixent(R) (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) ...
    12:29a ET September 22 '25 GlobeNewswire
    Regeneron Donates Ebola Treatment for Use in Countries Most at Risk o...
    7:00a ET September 19 '25 GlobeNewswire
    Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve...
    9:30a ET September 17 '25 GlobeNewswire
    Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare ...
    7:00a ET September 17 '25 GlobeNewswire
    Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates App...
    12:33p ET September 16 '25 PR Newswire Europe
    Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates App...
    12:30p ET September 16 '25 CNW Group
    REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regener...
    5:46p ET September 9 '25 GlobeNewswire

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2025 All rights reserved.